Ageing Pipeline Review, H2 2015
Summary
Global Markets Directs, Ageing Pipeline Review, H2 2015, provides an overview of the Ageings therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Ageing, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ageing and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Ageing
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Ageing and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Ageing products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Ageing pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Ageing
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Ageing pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ageing Overview 7
Therapeutics Development 8
Pipeline Products for Ageing - Overview 8
Pipeline Products for Ageing - Comparative Analysis 9
Ageing - Therapeutics under Development by Companies 10
Ageing - Therapeutics under Investigation by Universities/Institutes 11
Ageing - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Ageing - Products under Development by Companies 14
Ageing - Products under Investigation by Universities/Institutes 15
Ageing - Companies Involved in Therapeutics Development 16
Bioo Therapeutics 16
Mapreg S.A.S. 17
Neuralstem, Inc. 18
RepliCel Life Sciences, Inc. 19
RXi Pharmaceuticals Corporation 20
Theravasc, Inc. 21
Varinel, Inc. 22
Ageing - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles BIOO-4 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
BIOO-7 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Drugs for Ageing - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MAP-46 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MG-29 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MMP-26051 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MMP-26052 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NSI-189 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RCS-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
sirolimus - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule for Alzheimer's Disease and Ageing - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
sodium nitrite SR - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TM-5441 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Transilon - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VAR-10303 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Ageing - Recent Pipeline Updates 50
Ageing - Dormant Projects 54
Ageing - Product Development Milestones 55
Featured News & Press Releases 55
Sep 15, 2015: RepliCel Life Sciences Announces Initiation of Clinical Site and Participant Recruitment for European Skin Aging Study 55
Jul 21, 2015: RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial 55
Oct 09, 2014: RepliCel to Present Commercial and Clinical Update on RCS-01 at BioJapan 2014 World Business Forum 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58
List Of Tables
Number of Products under Development for Ageing, H2 2015 8
Number of Products under Development for Ageing - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Ageing - Pipeline by Bioo Therapeutics, H2 2015 16
Ageing - Pipeline by Mapreg S.A.S., H2 2015 17
Ageing - Pipeline by Neuralstem, Inc., H2 2015 18
Ageing - Pipeline by RepliCel Life Sciences, Inc., H2 2015 19
Ageing - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 20
Ageing - Pipeline by Theravasc, Inc., H2 2015 21
Ageing - Pipeline by Varinel, Inc., H2 2015 22
Assessment by Monotherapy Products, H2 2015 23
Number of Products by Stage and Target, H2 2015 25
Number of Products by Stage and Mechanism of Action, H2 2015 27
Number of Products by Stage and Route of Administration, H2 2015 29
Number of Products by Stage and Molecule Type, H2 2015 31
Ageing Therapeutics - Recent Pipeline Updates, H2 2015 50
Ageing - Dormant Projects, H2 2015 54
List Of Figures
Number of Products under Development for Ageing, H2 2015 8
Number of Products under Development for Ageing - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 23
Number of Products by Targets, H2 2015 24
Number of Products by Stage and Targets, H2 2015 24
Number of Products by Mechanism of Actions, H2 2015 26
Number of Products by Stage and Mechanism of Actions, H2 2015 26
Number of Products by Routes of Administration, H2 2015 28
Number of Products by Stage and Routes of Administration, H2 2015 28
Number of Products by Molecule Types, H2 2015 30
Number of Products by Stage and Molecule Types, H2 2015 30
